The vision of the FY22 DMDRP is to preserve and improve the function and quality of life and to extend the lifespan of all individuals with Duchenne. As such, the DMDRP seeks to support the discovery and development of therapeutics for Duchenne for the benefit of military beneficiaries and the general public, from the characterization of pathophysiology through rigorous preclinical and clinical studies. Additionally, the DMDRP supports the efforts of the National Institutes of Health (NIH) Muscular Dystrophy Coordinating Committee (MDCC) and the 2015 MDCC Action Plan for the Muscular Dystrophies, which prioritizes the needs to improve treatments and reduce the disease burden for muscular dystrophy, including DMD.
Awards:
The anticipated direct costs budgeted for the entire period of performance for an FY22 DMDRP Translational Research Award will not exceed $1.25M or $1.35M for the Early-Career Partnering PI Option.
Anticipated Funding Amount:
$4,160,000
Letter of Intent:
Please contact the program director.
Preliminary Proposal Due Date(s):
5:00 p.m. Eastern time (ET), August 3, 2022
Full Proposal Submission Deadline:
11:59 p.m. ET, November 15, 2022
Contacts:
CDMRP Help Desk; Phone: 301-682-5507; Email: help@eBRAP.org
